Management of Graves Disease with Non-Compressive Goitre Presenting with Unilateral Facial Swelling and Back Pain
The unilateral facial swelling in the early morning strongly suggests Graves' orbitopathy (GO) requiring urgent ophthalmologic evaluation, while the back pain warrants investigation for potential complications of hyperthyroidism or unrelated pathology. The non-compressive goitre itself does not require immediate intervention beyond standard Graves' disease management.
Immediate Assessment Required
For Unilateral Facial Swelling
The morning facial swelling pattern is highly concerning for unilateral Graves' orbitopathy, which can occur even with euthyroid status 1. You must urgently assess for:
- Visual acuity and color vision - any recent decline indicates dysthyroid optic neuropathy requiring immediate referral 2
- Proptosis and extraocular muscle involvement - perform exophthalmometry
- Corneal exposure - check for lagophthalmos and corneal opacity/ulcer risk 2
- Ocular subluxation 2
Urgent ophthalmologic referral is mandatory if any of these features are present 2. Even without these severe features, unilateral GO requires joint endocrinology-ophthalmology management 1.
For Back Pain
Investigate for:
- Vertebral compression fractures (hyperthyroidism-induced osteoporosis)
- Muscle weakness/myopathy from thyrotoxicosis
- Unrelated musculoskeletal pathology
Primary Graves' Disease Management
Initiate antithyroid drug therapy immediately to achieve euthyroid status regardless of which definitive treatment is ultimately chosen 3.
First-Line Medical Treatment
- Methimazole (thiamazole) or carbimazole is preferred over propylthiouracil except in first trimester pregnancy 3, 4, 5
- Continue for 12-18 months initially 4, 5, 6
- Monitor free T4 and TSH every 1-2 months for first 6 months, with first assay within 2-4 weeks 2
Definitive Treatment Considerations
Given the non-compressive goitre, three options exist after achieving euthyroid status 3:
- Continue antithyroid drugs (12-18 months course, ~50% remission rate) 4, 5, 6
- Radioactive iodine (RAI) - CONTRAINDICATED if active/moderate GO is confirmed 4, 5
- Total thyroidectomy - preferred if moderate GO present, as it avoids RAI-associated worsening of orbitopathy 2, 6
Critical Management Algorithm for GO
If mild GO confirmed:
- Selenium 100 mg twice daily for 6 months improves quality of life and inflammatory signs 2
- Local measures: dark glasses, artificial tears, elevated bed-head 2
- Continue antithyroid drugs until GO becomes inactive 2
If moderate-to-severe GO confirmed:
- Glucocorticoids are first-line treatment 2
- Avoid radioiodine - it can worsen or induce GO in 15-20% of patients 5, 6
- If RAI absolutely necessary with mild/active GO, use oral corticosteroid prophylaxis (0.3-0.5 mg/kg/day) starting 1-3 days after RAI, tapering over 3 months 2
- Consider total thyroidectomy as definitive treatment - this is preferred when moderate GO coexists with Graves' disease requiring definitive therapy 6
Key Pitfalls to Avoid
- Do not dismiss unilateral presentation - GO can be unilateral even in bilobar Graves' disease 7, 1
- Do not use RAI if any active orbitopathy present - this is an absolute contraindication 4
- Do not delay ophthalmologic assessment - visual loss from dysthyroid optic neuropathy can be irreversible 2
- Ensure smoking cessation - smoking significantly worsens GO outcomes 2, 5
- Avoid hypothyroid episodes - these can worsen orbitopathy 2
Monitoring Strategy
- Ophthalmologic follow-up every 3-6 months until GO inactive 2
- TSH-R antibody levels at 12-18 months to guide continuation vs. definitive therapy 4, 5
- Thyroid function every 1-2 months initially 2
- Bone density assessment given back pain and hyperthyroidism risk for osteoporosis
The presence of unilateral facial swelling fundamentally alters your treatment approach - if moderate GO is confirmed, total thyroidectomy becomes the preferred definitive treatment over RAI 2, 6.